North America Cold Sore Treatment Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • Sep 2021
  • North America
  • 350 Pages
  • No of Tables: 80
  • No of Figures: 47

North America Cold Sore Treatment Market, By Strain Type (Herpes Simplex Type-1 Virus, Herpes Simplex Type-2 Virus), Therapeutics Type (Antiviral Agents, Analgesic Agents, Others), Drug Type (Branded and Generics), Dosage Type (Oral, Topical and Others), End User (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada and Mexico) Industry Trends and Forecast to 2028

North America Cold Sore Treatment MarketMarket Analysis and Insights: North America Cold Sore Treatment Market

The cold sore treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.0% in the forecast period of 2021 to 2028 and is expected to reach USD 722.89 million by 2028. The rising prevalence of herpes simplex virus (HSV) and proliferation in modes of transmission of HSV are the major drivers which has propelled the demand of the cold sore treatment market in the forecast period.

Cold sores or oral herpes are small blisters kind abrasions that occur due to the infection caused by the herpes simplex virus (HSV). Cold sores generally occur on the face, around the lips, chin, cheeks and nostrils. They generally cause pain and itching before they burst. HSV is one of the most common viruses found to affect the global population and it is endemic throughout the world. Up to 90% of people around the world have at least one form of HSV.

The rising awareness programs regarding sexually transmitted diseases acts as driver for the cold sore treatment market. The lack of awareness about the disease would lead to rapid spread of the disease and hence prevention would be difficult. It would result in delay in drug distribution and this factor would hamper the cold sore treatment market growth. The rising disposable income acts as an opportunity for the growth of the cold sore treatment market. The rise in resistance towards acyclovir would result in exploitation of novel drugs being developed for antiviral therapy, this factor will pose as a challenge in the cold sore treatment market.   

The cold sore treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the cold sore treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Cold Sore Treatment MarketCold Sore Treatment Market Scope and Market Size

The cold sore treatment market is segmented into six notable segments which are based on the strain type, therapeutics type, drug type, dosage type, end user, distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of strain type, the cold sore treatment market is segmented into herpes simplex type-1 virus (HSV) and herpes simplex type-2 virus (HSV). In 2021, herpes simplex type-1 virus (HSV) segment is dominating due to its rapidly increasing prevalence worldwide.  
  • On the basis by therapeutics, the cold sore treatment market is segmented into antiviral agents, analgesic agents and others. In 2021, antiviral agents segment is expected to dominate due to the increased count of infectious diseases caused by herpes simplex virus and enhanced product pipeline in antiviral agents.
  • On the basis of drug type, the cold sore treatment market is segmented into branded and generics. In 2021, generics segment is dominating because it’s less expensive as compared to branded drugs and due to the economical nature and increased usage for the treatment of cold sores.
  • On the basis of dosage type, the cold sore treatment market is segmented into oral, topical and others. In 2021, oral segment is expected to dominate because of its ease of absorption and flexibility to accommodate various types of drugs.
  • On the basis of end user, the cold sore treatment market is segmented into hospitals, homecare, specialty clinics and others. In 2021, homecare segment is dominating due to the ease in treatment at home and easy availability of drugs.
  • On the basis of distribution channel, the cold sore treatment market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. In 2021, hospital pharmacy segment is expected to dominate due to the rise in access to cold sore medications and surge in number of prescriptions of cold sore medications on a daily basis.

North America Cold Sore Treatment Market Country Level Analysis

North America cold sore treatment market is analysed and market size information is based on the country, strain type, therapeutics type, drug type, dosage type, end user, distribution channel as referenced above.

The countries covered in the North America cold sore treatment market report are the U.S., Canada and Mexico.

North America is expected to dominate the cold sore treatment market due to the increasing incidence of HSV infection among women in the region. The U.S. is expected to dominate in the North America cold sore treatment market and leading the growth in the region due to continuous increase in patient population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Strategic Initiatives by Manufacturers is Creating New Opportunities for Players in the Cold Sore Treatment Market 

The cold sore treatment market also provides you with detailed market analysis for every country growth in aesthetic industry with cold sore treatment sales, impact of advancement in the cold sore treatment and changes in regulatory scenarios with their support for the cold sore treatment market. The data is available for historic period 2011 to 2019.   

Competitive Landscape and Cold Sore Treatment Market Share Analysis

The cold sore treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to cold sore treatment market.

The companies covered in the North America cold sore treatment market report are Merix Pharmaceutical Corp., GlaxoSmithKline plc, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals, Inc., U.S.A. (a subsidiary of Glenmark Pharmaceutical Ltd.), Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Cipla Limited, AiCuris GmbH & Co. KG, Ortho Dermatologics’ (a division of Bausch Health Companies Inc.), FOUNDATION CONSUMER HEALTHCARE, Sqaurex, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Viatris Inc., Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), WOCKHARDT, Novartis AG, Jubilant Cadista (a subsidiary of Jubilant Life Sciences Ltd.), Hikma Pharmaceuticals PLC, Hetero Healthcare Limited, Apotex Inc., HRA Pharma among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.  

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the cold sore treatment market.

For instance,  

  • In December 2020, GlaxoSmithKline plc and Sanofi Inc. had declared the delay in the adjuvant recombinant protein based COVID-19 vaccine programme to enhance immune response in the elderly population. This initiative by both the companies would result in delay of the cold sore treatment products, less revenue and less growth in the market.

Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the cold sore treatment market which also provides the benefit for organisation to improve their offering for cold sore treatment.  

Customization Available: North America Cold Sore Treatment Market  

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 NORTH AMERICACOLD SORE TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 GENERIC DRUGS USED FOR THE TREATMENT OF HSV (COLD SORES)

TABLE 3 NORTH AMERICA COLD SORE TREATMENT MARKET, BY STRAIN TYPE 2019-2028 (USD MILLION)

TABLE 4 NORTH AMERICA HERPES SIMPLEX TYPE 1 VIRUS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA HERPES SIMPLEX TYPE 2 VIRUS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 NORTH AMERICA COLD SORE TREATMENT MARKET, BY THERAPEUTICS 2019-2028 (USD MILLION)

TABLE 7 NORTH AMERICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY REGION 2019-2028 (USD MILLION)

TABLE 8 NORTH AMERICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)

TABLE 9 NORTH AMERICA ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 NORTH AMERICA ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2019-2028 (USD MILLION)

TABLE 11 NORTH AMERICA OTHERS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 NORTH AMERICA COLD SORE TREATMENT MARKET, BY DRUG TYPE 2019-2028 (USD MILLION)

TABLE 13 NORTH AMERICA GENERICS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA BRANDED IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 NORTH AMERICA BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA COLD SORE TREATMENT MARKET, BY DOSAGE TYPE 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA ORAL IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 NORTH AMERICA ORAL SEGMENT IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA TOPICAL SEGMENT IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 NORTH AMERICA TOPICAL SEGMENT IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2019-2028 (USD MILLION)

TABLE 22 NORTH AMERICA OTHERS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA COLD SORE TREATMENT MARKET, BY END USER 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA HOSPITALS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA HOSPITALS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA SPECIALTY CLINICS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 NORTH AMERICA OTHERS IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 NORTH AMERICA COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)

TABLE 29 NORTH AMERICA HOSPITALS PHARMACY IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA ONLINE PHARMACY IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA RETAIL PHARMACY IN COLD SORE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 NORTH AMERICA COLD SORE TREATMENT MARKET, COUNTRY, 2021-2028 (USD MILLION)

TABLE 33 NORTH AMERICA COLD SORE TREATMENT MARKET, BY STRAIN TYPE, 2021-2028 (USD MILLION )

TABLE 34 NORTH AMERICA COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2021-2028 (USD MILLION)

TABLE 35 NORTH AMERICA ANTIVIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2021-2028 (USD MILLION)

TABLE 36 NORTH AMERICA ANALGESIC AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2021-2028 (USD MILLION)

TABLE 37 NORTH AMERICA COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 38 NORTH AMERICA GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 39 NORTH AMERICA BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 40 NORTH AMERICA COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2021-2028 (USD MILLION)

TABLE 41 NORTH AMERICA ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2021-2028 (USD MILLION)

TABLE 42 NORTH AMERICA TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2021-2028 (USD MILLION)

TABLE 43 NORTH AMERICA COLD SORE TREATMENT MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 44 NORTH AMERICA COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 45 U.S. COLD SORE TREATMENT MARKET, BY STRAIN TYPE , 2021-2028 (USD MILLION )

TABLE 46 U.S. COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2021-2028 (USD MILLION )

TABLE 47 U.S. ANTI-VIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2021-2028 (USD MILLION )

TABLE 48 U.S. ANALGESICS AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2021-2028 (USD MILLION)

TABLE 49 U.S. COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 50 U.S. GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 51 U.S. BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE , 2021-2028 (USD MILLION)

TABLE 52 U.S. COLD SORE TREATMENT MARKET, BY DOSAGE TYPE , 2021-2028 (USD MILLION)

TABLE 53 U.S. ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE , 2021-2028 (USD MILLION)

TABLE 54 U.S. TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE, 2018-2027 (USD MILLION)

TABLE 55 U.S. COLD SORE TREATMENT MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 56 U.S. COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 57 CANADA COLD SORE TREATMENT MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION )

TABLE 58 CANADA COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2021-2028 (USD MILLION )

TABLE 59 CANADA ANTI-VIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2021-2028 (USD MILLION )

TABLE 60 CANADA ANALGESICS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2021-2028 (USD MILLION)

TABLE 61 CANADA COLD SORE TREATMENT MARKET, BY DRUG TYPE , 2021-2028 (USD MILLION)

TABLE 62 CANADA GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE TYPE, 2021-2028 (USD MILLION)

TABLE 63 CANADA BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 64 CANADA COLD SORE TREATMENT MARKET, BY DOSAGE TYPE , 2021-2028 (USD MILLION)

TABLE 65 CANADA ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE , 2021-2028 (USD MILLION)

TABLE 66 CANADA TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE , 2021-2028 (USD MILLION)

TABLE 67 CANADA COLD SORE TREATMENT MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 68 CANADA COLD SORE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 69 MEXICO COLD SORE TREATMENT MARKET, BY STRAIN TYPE, 2021-2028 (USD MILLION )

TABLE 70 MEXICO COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2021-2028 (USD MILLION )

TABLE 71 MEXICO ANTI-VIRAL AGENTS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS, 2021-2028 (USD MILLION )

TABLE 72 MEXICO ANALGESICS IN COLD SORE TREATMENT MARKET, BY THERAPEUTICS , 2021-2028 (USD MILLION)

TABLE 73 MEXICO COLD SORE TREATMENT MARKET, BY DRUG TYPE , 2021-2028 (USD MILLION)

TABLE 74 MEXICO GENERICS IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 75 MEXICO BRANDED IN COLD SORE TREATMENT MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 76 MEXICO COLD SORE TREATMENT MARKET, BY DOSAGE TYPE , 2021-2028 (USD MILLION)

TABLE 77 MEXICO ORAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE , 2021-2028 (USD MILLION)

TABLE 78 MEXICO TOPICAL IN COLD SORE TREATMENT MARKET, BY DOSAGE TYPE , 2021-2028 (USD MILLION)

TABLE 79 MEXICO COLD SORE TREATMENT MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 80 MEXICO COLD SORE TREATMENT MARKET, BY DISTRIBUTION TYPE, 2021-2028 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions